V. Ozdemir

发表

Could endogenous substrates of drug-metabolizing enzymes influence constitutive physiology and drug target responsiveness?

B. Williams-Jones, T. Someya, A. Gunes, 2006, Pharmacogenomics.

Vaccines of the 21st century and vaccinomics: data-enabled science meets global health to spark collective action for vaccine innovation.

Eugene Kolker, Vural Ozdemir, Bartha M. Knoppers, 2011, Omics : a journal of integrative biology.

Delivering on the Promise of Bioeconomy in the Developing World: Link It with Social Innovation and Education

Sandipan Ray, B. Nair, S. Srivastava, 2016 .

Ketoconazole-Associated Preferential Increase in Dopamine D2 Receptor Occupancy in Striatum Compared to Pituitary In Vivo: Role for Drug Transporters?

J. Mukherjee, C. Reist, C. Constantinescu, 2012, Journal of clinical psychopharmacology.

The United States of America and Scientific Research

Folker Meyer, Peter Arzberger, Winston Haynes, 2010, PloS one.

Personalized Medicine Beyond Genomics: New Technologies, Global Health Diplomacy and Anticipatory Governance.

D. Husereau, V. Ozdemir, S. Samper, 2009, Current pharmacogenomics and personalized medicine.

Are We Asking the Right Ethics Questions on Drug Shortages? Suggestions for a Global and Anticipatory Ethics Framework

B. Knoppers, Y. Joly, D. Avard, 2012, The American journal of bioethics : AJOB.

CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype–phenotype association study design in translational pharmacogenetics

N. Fukui, T. Sugai, T. Someya, 2011, Journal of psychopharmacology.

Asia-Pacific Health 2020 and Genomics without Borders: Co-Production of Knowledge by Science and Society Partnership for Global Personalized Medicine.

Vural Ozdemir, Toshiyuki Someya, Tikki Pang, 2011, Current pharmacogenomics and personalized medicine.

Nutriproteomics and Proteogenomics: Cultivating Two Novel Hybrid Fields of Personalized Medicine with Added Societal Value.

Bartha M Knoppers, Vural Ozdemir, Laurette Dubé, 2010, Current pharmacogenomics and personalized medicine.

Asymmetry in Scientific Method and Limits to Cross-Disciplinary Dialogue

S. Preskorn, B. Williams-Jones, S. Glatt, 2007, Journal of Investigative Medicine.

Genome-environment interactions and prospective technology assessment: evolution from pharmacogenomics to nutrigenomics and ecogenomics.

Eugene Kolker, Vural Ozdemir, Béatrice Godard, 2009, Omics : a journal of integrative biology.

Nutrigenomics and personalized diet: from molecule to intervention and nutri-ethics.

B. Godard, V. Ozdemir, 2008, Omics : a journal of integrative biology.

Towards an Ecology of Collective Innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA).

Yann Joly, Eugene Kolker, Emmanuelle Vaast, 2011, Current pharmacogenomics and personalized medicine.

Editorial (BIOQUEST India: A Global Biotechnology Forum for Knowledge-Based Innovation and Sustainable Development)

B. Nair, V. Ozdemir, Sanjeev Srivastava, 2013 .

Public Health Pharmacogenomics and the Design Principles for Global Public Goods - Moving Genomics to Responsible Innovation.

L. Ferguson, M. Masellis, V. Manolopoulos, 2013, Current pharmacogenomics and personalized medicine.

Aripiprazole (Otsuka Pharmaceutical Co).

J. Fourie, F. Ozdener, V. Ozdemir, 2002, Current opinion in investigational drugs.

Ethnocultural community leaders’ views and perceptions on biobanks and population specific genomic research: a qualitative research study

B. Godard, V. Ozdemir, Marilyn Fortin, 2010, Public understanding of science.

SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.

Wei Zhang, An Wang, V. Ozdemir, 2007, British journal of clinical pharmacology.

ACCE, Pharmacogenomics, and Stopping Clinical Trials: Time to Extend the CONSORT Statement?

B. Knoppers, Y. Joly, V. Ozdemir, 2011, The American journal of bioethics : AJOB.

Angel Philanthropy and Crowdfunding to Accelerate Cancer Research in Developing World

Sandipan Ray, V. Ozdemir, 2016 .

Second-Generation Antipsychotic Exposure and Metabolic-Related Disorders in Patients With Schizophrenia: An Observational Pharmacoepidemiology Study From 1988 to 2002

J. Mintz, C. Reist, V. Ozdemir, 2007, Journal of clinical psychopharmacology.

Containing Global Antibiotic Resistance: Ethical Drug Promotion in the Developing World

B. Williams-Jones, V. Ozdemir, B. Doizé, 2010 .

Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health

B. Godard, B. Williams-Jones, V. Ozdemir, 2008 .

Challenges for Corporate Ethics in Marketing Genetic Tests

B. Williams-Jones, V. Ozdemir, 2007 .

Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly.

V. Ozdemir, R. Shulman, 1997, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

Low-Dose Fluvoxamine as an Adjunct to Reduce Olanzapine Therapeutic Dose Requirements: A Prospective Dose-Adjusted Drug Interaction Strategy

S. Marder, L. Endrenyi, C. Reist, 2005, Journal of clinical psychopharmacology.

Reply to Democracy unleashed—unpacking the tooth fairy in drug industry R&D

B. Williams-Jones, V. Ozdemir, 2006, Nature Biotechnology.

Diagnosis and Pharmacological Treatment of Alcoholic Patients

C. Naranjo, V. Ozdemir, K. Bremner, 1994 .

Treatment of alcohol withdrawal syndrome.

C. Naranjo, V. Ozdemir, K. Bremner, 1994, Annals of medicine.

Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers.

C. Naranjo, N. Herrmann, R. Tyndale, 1999, Journal of clinical psychopharmacology.

Authors' Reply to Dr Cohen: "scientific standards: Critical comments on the pharmacoepidemiological study of second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia"

J. Mintz, C. Reist, V. Ozdemir, 2008 .

Multigenic traits and risk assessment in pharmacology: a population approach

W. Kalow, L. Tothfalusi, V. Ozdemir, 2001, The Pharmacogenomics Journal.

Concentration-Response Relationship for Fluvoxamine Using Remission as an Endpoint: A Receiver Operating Characteristics Curve Analysis in Major Depression

N. Fukui, T. Sugai, T. Someya, 2008, Journal of clinical psychopharmacology.

Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society.

Eugene Kolker, Vural Ozdemir, Toshiyuki Someya, 2009, Omics : a journal of integrative biology.

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.

A. Paterson, L. Endrenyi, B. Tang, 2000, Pharmacogenetics.

Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib

J. Pérez-Ruixo, V. Piotrovsky, V. Ozdemir, 2006, Cancer Chemotherapy and Pharmacology.

Shifting emphasis from pharmacogenomics to theragnostics

M. Tsuang, B. Williams-Jones, S. Glatt, 2006, Nature Biotechnology.

Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression

Vural Ozdemir, H. Ågren, S. Karlsson, 2009, Pharmacogenetics and genomics.

Cosegregation of Gastrointestinal Ulcers and Schizophrenia in a Large National Inpatient Discharge Database

M. Hashemzadeh, K. Ősapay, M. Jadus, 2007, Journal of Investigative Medicine.

Race as a variable in pharmacogenomics science: from empirical ethics to publication standards

B. Godard, J. Graham, V. Ozdemir, 2008, Pharmacogenetics and genomics.

Pharmacogenomics research involving racial classification: qualitative research findings on researchers' views, perceptions and attitudes towards socioethical responsibilities.

B. Godard, V. Ozdemir, Nathalie Égalité, 2007, Pharmacogenomics.

Abuse of Prescription and Licit Psychoactive Substances by the Elderly

C. Naranjo, N. Herrmann, V. Ozdemir, 1995 .

A Candidate Pathway Strategy for Integration of Pharmacogenomic Components of Variability in Antipsychotic Treatment Outcomes: A Focus on Aripiprazole

S. Marder, B. Williams-Jones, T. Someya, 2005 .

What Will Be the Role of Pharmacogenetics in Evaluating Drug Safety and Minimising Adverse Effects?

W. Kalow, N. Shear, V. Ozdemir, 2001, Drug safety.

The positive effect of black seed (Nigella sativa L.) essential oil on thyroid hormones in rats with hypothyroidism and hyperthyroidism.

V. Ozdemir, G. Avcı, E. Ulutaş, 2021, Journal of food biochemistry.

Democracy unleashed—unpacking the tooth fairy in drug industry R&D

B. Williams-Jones, V. Ozdemir, 2006, Nature Biotechnology.

Evidence-based management of nutrigenomics expectations and ELSIs.

B. Godard, V. Ozdemir, 2007, Pharmacogenomics.

Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines

L. Bertilsson, C. Reist, J. Graham, 2006, Expert opinion on pharmacotherapy.

Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia

J. Lieberman, S. Potkin, H. Meltzer, 2001, Molecular Psychiatry.

Mapping translational research in personalized therapeutics: from molecular markers to health policy.

Vural Ozdemir, Bryn Williams-Jones, Dan M Cooper, 2007, Pharmacogenomics.

Multigenic control of drug response and regulatory decision-making in pharmacogenomics: The need for an upper-bound estimate of genetic contributions

L. Bertilsson, L. Endrenyi, W. Kalow, 2005 .

Forward Look: Tenth Anniversary of the Human Genome Sequence and 21 Century Postgenomics Global Health - A Close Up on Africa and Women's Health.

Yann Joly, Vural Ozdemir, Sandipan Ray, 2011, Current pharmacogenomics and personalized medicine.

Socio-ethical analysis of equity in access to nutrigenomics interventions for obesity prevention: a focus group study.

B. Godard, V. Ozdemir, Lise Lévesque, 2008, Omics : a journal of integrative biology.

The science of pharmacological variability: An essay

B K Tang, L. Endrenyi, B. Tang, 1999, Clinical pharmacology and therapeutics.

Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics.

V. Ozdemir, L. Albers, 2004, Current medicinal chemistry.

Survival Rate and Causes of Mortality in the Elderly with Depression

T. Someya, Kuniaki Takahashi, V. Ozdemir, 2007, Journal of Investigative Medicine.

Bernard Lerer: recipient of the 2014 inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics).

E. Hafen, E. Kolker, E. Vayena, 2014, Omics : a journal of integrative biology.

Social innovation with proteomics technology

Sanjeeva Srivastava, E. Dove, V. Ozdemir, 2015 .

Steering vaccinomics innovations with anticipatory governance and participatory foresight.

Bartha M Knoppers, Vural Ozdemir, B. Knoppers, 2011, Omics : a journal of integrative biology.

CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6–serotonin–dopamine crosstalk revisited

J. Kennedy, L. Bertilsson, L. Endrenyi, 2007, Pharmacogenetics and genomics.

Integrating anticipated nutrigenomics bioscience applications with ethical aspects.

B. Godard, B. Gremmen, V. Ozdemir, 2008, Omics : a journal of integrative biology.

Opportunities and challenges for the life sciences community.

Eugene Kolker, Vural Ozdemir, Elizabeth Stewart, 2012, Omics : a journal of integrative biology.

Novelty seeking and the dopamine D4 receptor gene (DRD4) revisited in Asians: Haplotype characterization and relevance of the 2‐repeat allele

Vural Ozdemir, Eric Wang, Christopher Reist, 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

One Size Does Not Fit All: Toward “Upstream Ethics”?

Vural Ozdemir, Bartha Maria Knoppers, B. Knoppers, 2010, The American journal of bioethics : AJOB.

Pharmacogenomics: Reflecting on the Old and New Social, Ethical and Policy Issues in Postgenomics Medicine

V. Ozdemir, 2010 .

Pharmacogenomics and the Promise of Personalized Medicine

B. Lerer, V. Ozdemir, 2005 .

Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes.

J. Kennedy, M. Masellis, V. Ozdemir, 2001, Journal of biochemical and biophysical methods.

CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine

L. Endrenyi, W. Kalow, V. Ozdemir, 2007, Pharmacogenetics and genomics.

All the post-genomic world is a stage: the actors and narrators required for translating pharmacogenomics into public health.

Vural Ozdemir, Edward S Dove, E. Dove, 2013, Personalized medicine.

Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin.

Wei Zhang, Vural Ozdemir, Lan Fan, 2007, Pharmacogenomics.

Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?

C. Naranjo, J. Fourie, U. Busto, 1996, Clinical pharmacokinetics.

Hypoglycaemia induced by second generation antipsychotic agents in schizophrenic non-diabetic patients

N. Fukui, T. Someya, V. Ozdemir, 2009, BMJ : British Medical Journal.

The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline.

C. Naranjo, N. Herrmann, E. Sellers, 1998, Journal of clinical psychopharmacology.

Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology.

Rekha Jain, Sanjeeva Srivastava, Vural Ozdemir, 2011, Current pharmacogenomics and personalized medicine.

End of the Beginning and Public Health Pharmacogenomics: Knowledge in 'Mode 2' and P5 Medicine.

Vural Ozdemir, Erik Fisher, Edward S Dove, 2012, Current pharmacogenomics and personalized medicine.

Policy and data-intensive scientific discovery in the beginning of the 21st century.

Eugene Kolker, Bartha M Knoppers, Vural Ozdemir, 2011, Omics : a journal of integrative biology.

Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.

C. Naranjo, N. Herrmann, E. Sellers, 1998, Journal of clinical psychopharmacology.

Effect of venlafaxine on imipramine metabolism

R. Poland, D. Helmeste, C. Reist, 2000, Psychiatry Research.

Beyond ELSIs: Where to from Here? From “Regulating” to Anticipating and Shaping the Innovation Trajectory in Personalized Medicine

Vural Ozdemir, Bartha Maria Knoppers, Yann Joly, 2013 .

What To Do When the Risk Environment Is Rapidly Shifting and Heterogeneous? Anticipatory Governance and Real-Time Assessment of Social Risks in Multiply Marginalized Populations Can Prevent IRB Mission Creep, Ethical Inflation or Underestimation of Risks

Vural Ozdemir, V. Ozdemir, 2009, The American journal of bioethics : AJOB.

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia

M Masellis, H. Y. Meltzer, S. Potkin, 2000, Molecular Psychiatry.

CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.

B. Tang, W. Kalow, C. Reist, 2001, Journal of Clinical Psychopharmacology.

Race as a variable in pharmacogenomics science: from empirical ethics to publication standards

B. Godard, J. Graham, V. Ozdemir, 2008, Pharmacogenetics and genomics.

Steering vaccinomics innovations with anticipatory governance and participatory foresight.

B. Knoppers, V. Ozdemir, Samer Faraj, 2011, Omics : a journal of integrative biology.

Bernard Lerer: recipient of the 2014 inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics).

E. Hafen, E. Kolker, E. Vayena, 2014, Omics : a journal of integrative biology.

Standardization and omics science: technical and social dimensions are inseparable and demand symmetrical study.

J. Graham, V. Ozdemir, F. McDonald, 2010, Omics : a journal of integrative biology.

DELSA Global for “Big Data” and the Bioeconomy: Catalyzing Collective Innovation

Eugene Kolker, Vural Ozdemir, Elizabeth Stewart, 2012 .

ACCE, Pharmacogenomics, and Stopping Clinical Trials: Time to Extend the CONSORT Statement?

B. Knoppers, Y. Joly, V. Ozdemir, 2011, The American journal of bioethics : AJOB.

Socio-ethical analysis of equity in access to nutrigenomics interventions for obesity prevention: a focus group study.

B. Godard, V. Ozdemir, Lise Lévesque, 2008, Omics.

5-Hydroxytryptamine-2A receptor gene (HTR 2 A) candidate polymorphism (T 102 C): Role for human platelet function under pharmacological challenge ex vivo.

K. Erol, F. Ozdener, V. Ozdemir, 2005, Methods and findings in experimental and clinical pharmacology.